Joseph R. Shaw: Join The Annual CanVECTOR National Thrombosis Seminar on Precision in DOAC Reversal
Joseph R. Shaw, Director of Research+ Program at Ottawa Department of Medicine, EHJ-CVP Associate Editor at European Heart Journal, shared on LinkedIn about a recent article published in JTH, adding:
”In my role as Chair of the CanVECTOR National Thrombosis Seminars, I’m pleased to share the final seminar of our 2025–2026 academic year.
Join us for: Working Towards Precision in DOAC Reversal Through Harnessing the Power of a National, Trainee-Led Network in the UK
Monday, June 8, 2026 | 12:00–12:45 p.m. ET
Featuring Richard Buka, PhD, MBChB, University of Birmingham.
This session will examine what ‘precision’ in DOAC reversal looks like in real-world practice, including not only the choice of reversal strategy, such as andexanet alfa, idarucizumab, and 4-factor prothrombin complex concentrate (4F-PCC/PCC), but also administration logistics, timing, dosing, patient selection, governance, and the potential role of urgent DOAC drug levels.
The discussion will draw on insights from the HaemSTAR trainee-led network and the JTH paper, ‘A UK-wide analysis of 2265 patients receiving a reversal agent for direct oral anticoagulant-associated bleeding.’
Moderator: Joseph R. Shaw, MD MSc FRCPC DRCPSC (Ottawa Hospital Research Institute)
A QandA session will follow the presentation.”
Title: A UK-wide analysis of 2265 patients receiving a reversal agent for direct oral anticoagulant-associated bleeding
Authors: HaemSTAR Collaborators
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 20, 2026, 06:45Grant Garcia: Why Does a Blood Clot Diagnosis Immediately End an Athlete’s Season?
-
Oct 20, 2026, 06:35Parag Tamhankar: Landmark Study Reveals Genetic Spectrum and Targeted Therapies for ALPS in the Indian Population
-
Oct 20, 2026, 06:26Nina Houben: Neonatal Blood Transfusion Symposium and PhD Defense
-
Oct 20, 2026, 05:46Jan T. Kielstein: DNP Poisoning and Hemoadsorption The Limits of Rescue Therapy
-
Oct 20, 2026, 05:33Giulia Di Paolo: Connecting Plasma Donation to the Patients Who Depend on It
-
Oct 20, 2026, 05:20James Knowles: Exploring Plasma Manufacturing and Strengthening Industry Collaboration
-
Oct 20, 2026, 05:11Giuseppe Lippi։ Understanding Liver Test Abnormalities After AAV Gene Therapy
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question